       |
Technology
Epitarget AS is dedicated to developing drug formulations providing safe and effective treatment of cancer patients. The company currently conducts research and development in close collaboration with academic partners. Therapeutic Ultrasound - Ultrasound mediated drug release Cancer treatment based on radiation or chemotherapeutic drugs, have shown limited success due to general toxicity concerns. Epitarget is developing technology for local release of cytostatic drugs by means of ultrasound. Here, therapeutically active substances encapsulated within nano sized liposomes are administered to the patient and efficiently released at the site of the tumor by exposure to a defined ultrasound field. The company aims at developing sonosensitive (ultrasound sensitive) liposomal drug formulations and use established ultrasound technology to mediate release. Epitarget’s technology allows administration of higher concentrations of the drugs in question, in a limited and well-defined area minimizing unwanted systemic toxic effects. Furthermore, by including an array of substances into the nanoparticles, cancer tumors can be attacked by several treatment modes simultaneously. MR tracking of nanoparticles Epitarget has realized the need to monitor the spatial position, accumulation and concentration of drug carrying particles, as well as the need to monitor the efficiency of drug release. By incorporating contrast agents into drug delivery particles Epitarget has shown that particles may be tracked and drug release monitored to optimise local medical treatment. |
|
 |
||
